The question your buyer will ask
Every regulated buyer runs your product through the same filter — from a different seat.
"Who reviewed the output?"
A quality organization needs a named, credentialed reviewer in the loop before it can qualify your process for use in a regulated workflow.
"What's the context of use?"
FDA and EMA guidance on AI/ML in drug development turns on how a model is used and overseen — not just what it predicts.
"Where's the evidence?"
Procurement and sponsor diligence teams want a validation dossier, not a claim — something they can put in front of their own auditors.
Five ways we make your product defensible
Clinical-logic validation
Physician and specialist review of your product's clinical assumptions and outputs — the evidence base your buyers' QA teams require.
Expert-in-the-loop review, with SLAs
Named, credentialed reviewers on defined turnaround commitments — embedded in your product or your delivery workflow.
Regulatory positioning
FDA credibility framework, FDA–EMA AI principles, 21 CFR Part 11 alignment, and EU AI Act risk classification — explained in your buyer's language.
Product & workflow design with clinicians
Board-certified physicians and specialists in the design loop — so oversight is built into the workflow, not bolted on before a sales call.
Co-go-to-market
Joint positioning with CROs and sponsors who need exactly the validation layer your product is missing today.
Expert-in-the-Loop, as a service
The same discipline we run inside our own Medical Oversight Workbench, available for your product.
Named reviewers, real credentials
Not an anonymous pool. Each reviewer comes with a credential dossier your QA team — or your customer's — can qualify.
Defined SLAs and cadence
Turnaround commitments matched to your release cycle or signal volume — not a consultant's calendar.
A documented decision trail
Who reviewed, when, under what criteria, with what outcome — captured by default, retrievable on demand.
An assurance package your buyer can approve
Human-in-the-loop design, validation evidence, and audit trail assembled into one dossier — proof, not a claim.
Most AI pilots don't fail. They stall.
Industry-wide, only 22% of life-sciences leaders have scaled AI — and the wall is almost never the model. It's validation, governance, and the human-oversight design nobody scoped. We build the human-in-the-loop architecture and the assurance dossier that gets a conservative QA organization to yes.
- › Oversight design: what needs a human, at what step, signed how
- › Validation evidence mapped to your buyer's quality framework
- › The credentialed reviewers to run it — from day one
"The model worked. Then QA asked who signs off — and the pilot has been 'under review' ever since."
The most common way a good AI product stalls before a regulated sale — and the most fixable.
How we stay independent while we partner with vendors
We validate vendor products, partner commercially with some of them, and build our own Medical Oversight Workbench — so we're direct about how we keep those roles from blurring. Our physicians and specialists review against clinical and regulatory criteria set independently of any commercial relationship, our findings are documented the same way regardless of who the client is, and we disclose relevant commercial relationships (revenue share, referral fees, or co-development) to the parties who need to know. Independence in judgment is the product we sell — protecting it is not optional.
Educate · Evaluate · Execute — for vendors
Regulatory landscape briefing
Where FDA, EMA, and the EU AI Act actually land on AI in drug development and clinical operations — for your product team and your board.
Clinical validation & readiness assessment
A bounded review of your product's clinical logic and oversight design, scored against a regulatory readiness framework.
Ongoing review & co-go-to-market
Expert-in-the-loop review under SLA, a validation dossier your buyers can rely on, and joint go-to-market with CROs and sponsors.
Questions vendors ask us
Can your experts appear in our sales and marketing materials?
With written agreement, scoped to what was actually reviewed — we don't lend a name to a claim our review didn't cover.
Do you resell platforms?
No. We validate and review; where we have a commercial partnership with a vendor, we disclose it to the parties who need to know.
How do you avoid conflicts of interest?
The same clinical and regulatory criteria apply regardless of any commercial relationship, and findings are documented the same way every time. See the independence note above.
Discuss your validation requirement.
Bring us the product, the pilot, or the buyer's question you can't yet answer with proof.